Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
First Investment: 2023
In antibody therapy, researchers create custom-made antibodies that bind to cells such as tumor cells, flagging them for destruction by the immune system. It’s a powerful technology — but for some types of cells, there’s nowhere to attach an antibody. Solu Therapeutics literally bridges this gap using proprietary molecules called Cytotoxicity Targeting Chimeras (CyTaCs) that attach to target cells on one end and antibodies on the other. The company’s first clinical candidate will target blood cancers.
